# EDGAR Filing Document

**Accession Number:** 0001750149
**File Stem:** 9999999995-25-002070
**Filing Date:** 2025-6
**Character Count:** 1327
**Document Hash:** 7f09fa48f7e38e666715f4fa5f03b61f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999995-25-002070.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 9999999995-25-002070

**CONFORMED SUBMISSION TYPE**: EFFECT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250630

**EFFECTIVENESS DATE**: 20250627

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibikase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001750149
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263407249
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** EFFECT
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288213
- **FILM NUMBER:** 251088626

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 N. WEST STREET, SUITE 1200
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** (302) 295-3800

**MAIL ADDRESS:**
- **STREET 1:** 1000 N. WEST STREET, SUITE 1200
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

### UNITED STATES
### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## Notice of Effectiveness

**Date:** June 27, 2025

**Time:** 16:01:00

**Form Type:** S-3

---

**CIK:** 0001750149

**Company Name:** Inhibikase Therapeutics, Inc.

**File Number:** 333-288213